What do you think about adding pantoprazole routinely in all the patients' treatment regimens in the emergency department as well as in the medicine ward? Do you think it is necessary? And what guidelines should one follow before adding a PPI to any treatment regimen? What are the indications?
Reading File
Finding Sources
Finding Sources
Searching PubMed
proton pump inhibitor overuse inappropriate prescribing hospital
Searching the Web
PPI proton pump inhibitor indications guidelines 2024 stress ulcer prophylaxis emergency ward
Reading File
Reading File
Finding Sources
Searching PubMed
proton pump inhibitor inappropriate prescribing inpatient ward
Reading File
Finding Sources
Finding Sources
Searching PubMed
proton pump inhibitor harms risks Clostridium difficile fracture hypomagnesemia
Finding Sources
Finding Sources
Reading File
Reading File
Searching PubMed
proton pump inhibitor appropriate indications guidelines deprescribing
Reading Article
Reading Article
Reading File
I now have enough comprehensive information to give a thorough, well-sourced answer. Let me compile it.
Routine Pantoprazole in the ED and Medicine Ward: Is It Justified?
The short answer is no - routine pantoprazole for every admitted patient is not evidence-based and is associated with real harms. Here is a full breakdown.
1. The Problem with Blanket PPI Prescribing
This is one of the most well-documented examples of polypharmacy and drug overuse globally. A 2026 retrospective study across internal medicine wards (Kotoula et al., PMID: 42199367) found that among 852 admissions:
- 54% of admitted patients were on a PPI at some point during hospitalization
- Only ~48-49% of those new PPI prescriptions had an appropriate indication
- At discharge, ~56% of patients continued a PPI without a clearly appropriate indication
- Deprescribing was attempted in only 30% of cases where it was warranted
A 2023 cross-sectional study (Swed et al., PMID: 38026957) confirms that physician awareness of appropriate PPI use remains poor, and many prescriptions are written reflexively out of habit rather than clinical reasoning.
2. Evidence-Based Indications for PPIs
Per the 2025 evidence-based review (Andrawes et al., Medicina, PMID: 41010960) and multiple major textbooks (Harrison's, Goldman-Cecil, Washington Manual):
Established/Approved Indications
| Indication | Notes |
|---|---|
| Gastroesophageal reflux disease (GERD) | Especially erosive esophagitis; strongest indication |
| Peptic ulcer disease (PUD) - treatment | H. pylori eradication regimens include a PPI |
| NSAID-induced gastroduodenal ulcers | Prevention and treatment |
| GI prophylaxis in high-risk NSAID/antiplatelet users | Especially with history of GI bleed |
| Zollinger-Ellison syndrome | High-dose PPI required |
| Upper GI bleed (active/post-endoscopic hemostasis) | High-dose IV PPI post-endoscopy with high-risk stigmata; per ACG 2021 guidelines |
| H. pylori eradication | Component of triple/quadruple therapy |
| Stress ulcer prophylaxis (SUP) | Only in high-risk hospitalized patients (see below) |
| Barrett's esophagus | High-dose PPI + aspirin under investigation |
| Functional dyspepsia | Short-term, with evidence of symptom benefit |
- Goldman-Cecil Medicine, p. 1455; Harrison's Principles 22e, p. 2514; Yamada's Textbook of Gastroenterology, 7e
3. Stress Ulcer Prophylaxis: Who Actually Needs It?
This is where the "routine pantoprazole" habit most often originates. The evidence is clear:
"Prophylaxis against stress ulcers is not necessary for all ICU patients. It should only be administered to high-risk patients, such as those with coagulopathy or respiratory failure requiring mechanical ventilation."
- Harrison's Principles of Internal Medicine 22e, p. 2514
Primary Indications for SUP (per Washington Manual & Sabiston):
- Mechanical ventilation >48 hours
- Significant coagulopathy: platelets <50,000, INR >1.5, or PTT >2x ULN
Secondary/Supporting Indications (any 2 of the following):
- Upper GI bleed in the last year
- Brain or spinal cord injury
- Occult GI bleeding for ≥6 days
- High-dose steroids (>250 mg hydrocortisone equivalent/day)
- Sepsis
- ICU stay >1 week
What About the General Medicine Ward (Non-ICU)?
For non-ICU ward patients, the threshold is even higher:
- SUP is generally not indicated for patients simply admitted for pneumonia, ACS without coagulopathy, UTI, metabolic derangements, etc.
- The ACG/Am J Med 2022 guidance (Clarke et al.) specifically addresses this: PPIs for stress ulcer prophylaxis in hospitalized patients should be reserved for those with the above ICU-level risk factors
The REVISE trial (NEJM 2024, Cook et al.) - the largest and most recent RCT - showed clear benefit of IV pantoprazole 40mg daily in mechanically ventilated ICU patients, but this applies only to that specific population, not every ward admission.
4. Risks of Indiscriminate PPI Use
Long-term/indiscriminate PPI prescribing is not benign. Current evidence links it to:
| Adverse Effect | Strength of Evidence |
|---|---|
| Clostridioides difficile infection | Moderate - likely causal, especially with antibiotics |
| Hypomagnesemia | Well-established; monitor in long-term use |
| Vitamin B12 and iron deficiency | Reduced absorption with prolonged acid suppression |
| Osteoporotic fractures (hip, wrist, spine) | Observational association, especially in elderly |
| Community-acquired/nosocomial pneumonia | Plausible mechanism (gastric acid loss), some evidence |
| Chronic kidney disease | Observational association |
| Gastric cancer | Long-term PPI use post-H. pylori eradication associated with >2x risk (Cheung & Leung) - Yamada's Gastroenterology |
| Dementia | Observational, causality not established |
| Drug interactions | Especially with clopidogrel (CYP2C19), some cancer drugs |
- Andrawes et al., Medicina 2025 (PMID: 41010960); Yamada's Textbook of Gastroenterology 7e
5. When PPIs Are Indicated in the ED/Acute Setting
In the ED and acute ward, reasonable indications to start a PPI include:
- Active upper GI bleed or suspected peptic ulcer bleeding (pre- and post-endoscopy)
- NSAID-related gastric injury or in patients requiring ongoing NSAID/antiplatelet therapy who have risk factors (prior GI bleed, age >65, concurrent steroids or anticoagulants)
- Confirmed or suspected H. pylori - as part of eradication therapy
- Known GERD or erosive esophagitis - continuing an established indication
- ICU admission with mechanical ventilation or significant coagulopathy (SUP)
- High-dose corticosteroid pulse therapy combined with other bleeding risk factors
- Dual antiplatelet or anticoagulant therapy in patients with prior GI bleed
6. Guidelines for PPI Prescribing Practice
Key principles from multiple society guidelines (ACG, NICE, Canadian Deprescribing Network, AGA):
- Always document the indication before starting - "GI prophylaxis" alone is not an indication
- Set a duration at the time of prescribing - avoid open-ended prescriptions
- Review at every transition of care - ED to ward, ward to discharge
- Deprescribe on discharge if the indication no longer applies (e.g., patient was intubated but is now extubated and eating)
- Use the lowest effective dose - most patients do not need IV pantoprazole when oral is available
- For non-erosive GERD/functional dyspepsia: consider on-demand or intermittent dosing rather than continuous
- Consider switching to H2 receptor antagonists (famotidine) when full acid suppression is not required
Summary Verdict
Routine pantoprazole for every ED or ward patient is not justified. It is a form of irrational prescribing driven by habit, not evidence. The major harms - C. difficile infection, hypomagnesemia, drug interactions, potential long-term cancer and kidney risk - are real. In critically ill ventilated patients, PPIs are clearly beneficial. In general ward patients without risk factors, they cause harm without meaningful benefit.
A structured approach - asking "does this patient have a documented indication?" before every PPI prescription - is both clinically sound and what every major guideline recommends.
Key recent references:
- Andrawes M et al. PPIs - Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. Medicina 2025. PMID: 41010960
- Kotoula C et al. Deprescribing of PPIs in internal medicine in-patients. Explor Res Clin Soc Pharm 2026. PMID: 42199367
- Cook D et al. Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation (REVISE). NEJM 2024. PMID: 38875111
This is a shared conversation. Sign in to Orris to start your own chat.